Paragon Care Limited (ASX:PGC)

Market Cap	256.57M -59.2%
Revenue (ttm)	3.67B +8.5%
Net Income	-13.93M
EPS	-0.01
Shares Out	1.66B
PE Ratio	n/a
Forward PE	10.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,008,519
Open	0.1650
Previous Close	0.1650
Day's Range	0.1550 - 0.1650
52-Week Range	0.1350 - 0.4100
Beta	-0.32
Analysts	Buy
Price Target	0.25 (+61.29%)
Earnings Date	Jun 9, 2026

About Paragon Care

Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provides neonatal and paediatric assessment, including newborn hearing and vision screening, jaundice management, NICU video monitoring, brain monitoring, b...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2005
• Employees: 550
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PGC

Financial Performance

In fiscal year 2025, Paragon Care's revenue was 3.61 billion, an increase of 21.68% compared to the previous year's 2.97 billion. Earnings were 20.57 million, an increase of 151.52%.

Analyst Summary

According to 2 analysts, the average rating for PGC stock is "Buy." The 12-month stock price target is $0.25, which is an increase of 61.29% from the latest price.

Price Target

$0.25

(61.29% upside)

Analyst Consensus: Buy